• Argos Therapeutics Inc., of Durham, N.C., presented a high resolution immune monitoring analysis of Phase II study AGS-003-006, testing Arcelis immunotherapy AGS-003 in combination with Sutent (sunitinib, Pfizer Inc.) in patients with advanced renal cell carcinoma (RCC), with results showing a statistically significant correlation between antitumor memory T-cell responses and overall survival.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST